Tesamorelin Clinical Evidence HIV-associated visceral adiposity Randomized controlled trials demonstrated reductions in visceral adipose tissue in HIV-infected adults with lipodystrophy and excess abdominal fat
Healthcare providers assess each patient's complete medical history, current health status, and treatment goals to recommend evidence-based treatment options that may be appropriate for individual circumstances
Jun 1 2021;103(11):663-671
If activity levels are low, the body does not need to use large amounts of fat as fuel
However, clinical studies are not limited to the radiologic appearance, but also several other parameters such as time for cast removal, range of motion, VAS or DASH scores, etc
higher doses (3,000 mg/day) show greater efficacy[1][17] Minimum 24 weeks